Towards a point-of-care strip test to diagnose sickle cell anemia.

A rapid test to identify patients with sickle cell disease could have important benefits in low-resource settings. Sickle cell anemia (SCA) affects about 300,000 newborns each year, the majority of whom are born in sub-Saharan Africa. Low-cost therapies are available to treat SCA, but most countries...

Full description

Bibliographic Details
Main Authors: Meaghan Bond, Brady Hunt, Bailey Flynn, Petri Huhtinen, Russell Ware, Rebecca Richards-Kortum
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5433739?pdf=render
id doaj-251e530e5c3d4e80b1d84d7cff2f0639
record_format Article
spelling doaj-251e530e5c3d4e80b1d84d7cff2f06392020-11-25T01:24:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01125e017773210.1371/journal.pone.0177732Towards a point-of-care strip test to diagnose sickle cell anemia.Meaghan BondBrady HuntBailey FlynnPetri HuhtinenRussell WareRebecca Richards-KortumA rapid test to identify patients with sickle cell disease could have important benefits in low-resource settings. Sickle cell anemia (SCA) affects about 300,000 newborns each year, the majority of whom are born in sub-Saharan Africa. Low-cost therapies are available to treat SCA, but most countries in sub-Saharan Africa lack robust neonatal screening programs needed to identify patients in need of treatment. To address this need, we developed and evaluated a competitive lateral flow assay that identifies patients with SCA (genotype HbSS) in 15 minutes using undiluted whole blood. A small volume of blood (0.5 μL- 3 μL) is mixed with antibody-coated blue latex beads in a tube and applied to the strip. Strips are then placed in a well of running buffer and allowed to run for 10 minutes. Laboratory evaluation with samples containing different proportions of hemoglobin A (HbA) and hemoglobin S (HbS) indicated that the test should enable identification of SCA patients but not persons with sickle cell trait (SCT). We evaluated the test using 41 samples from individuals with SCA, SCT, and normal blood. With visual inspection or quantitative analysis, we found a 98% accuracy when differentiating SCA from normal and SCT samples as a group (90% sensitivity and 100% specificity for identifying SCA). This work demonstrates important steps towards making a lateral flow test for hemoglobinopathies more appropriate for point-of-care use; further work is needed before the test is appropriate for clinical use.http://europepmc.org/articles/PMC5433739?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Meaghan Bond
Brady Hunt
Bailey Flynn
Petri Huhtinen
Russell Ware
Rebecca Richards-Kortum
spellingShingle Meaghan Bond
Brady Hunt
Bailey Flynn
Petri Huhtinen
Russell Ware
Rebecca Richards-Kortum
Towards a point-of-care strip test to diagnose sickle cell anemia.
PLoS ONE
author_facet Meaghan Bond
Brady Hunt
Bailey Flynn
Petri Huhtinen
Russell Ware
Rebecca Richards-Kortum
author_sort Meaghan Bond
title Towards a point-of-care strip test to diagnose sickle cell anemia.
title_short Towards a point-of-care strip test to diagnose sickle cell anemia.
title_full Towards a point-of-care strip test to diagnose sickle cell anemia.
title_fullStr Towards a point-of-care strip test to diagnose sickle cell anemia.
title_full_unstemmed Towards a point-of-care strip test to diagnose sickle cell anemia.
title_sort towards a point-of-care strip test to diagnose sickle cell anemia.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description A rapid test to identify patients with sickle cell disease could have important benefits in low-resource settings. Sickle cell anemia (SCA) affects about 300,000 newborns each year, the majority of whom are born in sub-Saharan Africa. Low-cost therapies are available to treat SCA, but most countries in sub-Saharan Africa lack robust neonatal screening programs needed to identify patients in need of treatment. To address this need, we developed and evaluated a competitive lateral flow assay that identifies patients with SCA (genotype HbSS) in 15 minutes using undiluted whole blood. A small volume of blood (0.5 μL- 3 μL) is mixed with antibody-coated blue latex beads in a tube and applied to the strip. Strips are then placed in a well of running buffer and allowed to run for 10 minutes. Laboratory evaluation with samples containing different proportions of hemoglobin A (HbA) and hemoglobin S (HbS) indicated that the test should enable identification of SCA patients but not persons with sickle cell trait (SCT). We evaluated the test using 41 samples from individuals with SCA, SCT, and normal blood. With visual inspection or quantitative analysis, we found a 98% accuracy when differentiating SCA from normal and SCT samples as a group (90% sensitivity and 100% specificity for identifying SCA). This work demonstrates important steps towards making a lateral flow test for hemoglobinopathies more appropriate for point-of-care use; further work is needed before the test is appropriate for clinical use.
url http://europepmc.org/articles/PMC5433739?pdf=render
work_keys_str_mv AT meaghanbond towardsapointofcarestriptesttodiagnosesicklecellanemia
AT bradyhunt towardsapointofcarestriptesttodiagnosesicklecellanemia
AT baileyflynn towardsapointofcarestriptesttodiagnosesicklecellanemia
AT petrihuhtinen towardsapointofcarestriptesttodiagnosesicklecellanemia
AT russellware towardsapointofcarestriptesttodiagnosesicklecellanemia
AT rebeccarichardskortum towardsapointofcarestriptesttodiagnosesicklecellanemia
_version_ 1725119021006716928